Table 5.
Risk of involvement in a motor vehicle collision by medication exposure categorized by pharmaceutical sub-class
| Medication sub-class | Number of individuals taking medication (N) | 1:4 Matched control periodsa | |||
|---|---|---|---|---|---|
| Model 1 Odds ratio (95 % CI) | Model 2 Odds ratio (95 % CI) | ||||
| Anticholesteremics | 31 | 1.50 | (0.44, 5.18) | 0.42 | (0.08, 2.21) |
| Anticoagulants | 20 | 3.59 | (0.84, 15.28) | 2.29 | (0.35, 15.19) |
| Antidepressants | 30 | 2.05 | (0.59, 7.16) | 0.50 | (0.09, 2.67) |
| Antihyperglycemics | 22 | 15.36 | (1.79, 132.0) | 2.24 | (0.17, 29.84) |
| Antihypertensives | 39 | 3.32 | (1.15, 9.62) | 1.24 | (0.29, 5.32) |
| Benzodiazepines | 21 | 1.96 | (0.58, 6.62) | 0.71 | (0.15, 3.34) |
| Narcotic Analgesics | 41 | 1.56 | (0.72, 3.39) | 0.94 | (0.32, 2.75) |
aConditional logistic regression was used to calculate the odds ratios and 95 % CI. Each case’s medication exposure during the 14 day risk period immediately before the crash was matched to four separate control periods up to one year before the collision to assess if medication use during the risk period was associated with an increase of motor vehicle collision compared to control periods. Model 1 is the crude estimate (i.e. unadjusted) while Model 2 was adjusted for the number of medications a person was taking during each case and control period